ABT263 is sufficient to overcome resistance to an EZH2 inhibitor and synergizes with an EZH2 inhibitor in vivo in ARID1A-inactivated ovarian tumor mouse models. This evidence concerns the gene ARID1A and ovarian neoplasm.